Vivani Medical VANI Biopharm Division — Development Expense

Similar metrics at other companies

PFEBiopharma — Research and development expenses

$2.14B+10.1%

OPKPharmaceutical — Research And Development Expense

$28.75M-4.9%

ANABBiopharma Company — Research And Development Expense Excluding Acquired In Process Cost

$34.9M-8.4%

VRTXPharmaceuticals — Development expenses

$756.6M-2.2%

BAXPharmaceuticals — Research and development expenses

$22M-15.4%

BDXBioPharma Systems — Research and development expense

$17M-5.6%

Questions, answered.

What is Vivani Medical's biopharm division — development expense?

Vivani Medical (VANI) reported biopharm division — development expense of $1.01M in Q1 2026.

How has Vivani Medical's biopharm division — development expense changed year-over-year?

Vivani Medical's biopharm division — development expense increased by 21.9% year-over-year, from $827K to $1.01M.

What is the long-term trend for Vivani Medical's biopharm division — development expense?

Over 2 years (2023 to 2025), Vivani Medical's biopharm division — development expense has grown at a 29.6% compound annual growth rate (CAGR), from $2.58M to $4.33M.

What does biopharm division — development expense mean?

Represents the direct costs associated with the research and development of drug delivery technologies and preclinical candidates within the biopharmaceutical segment. This is a critical indicator of the segment's investment in its future product pipeline and technological innovation. High levels of development expense are typical for companies focused on long-term clinical advancement.